These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32339438)

  • 21. Gene Expression Classifier vs Targeted Next-Generation Sequencing in the Management of Indeterminate Thyroid Nodules.
    Livhits MJ; Kuo EJ; Leung AM; Rao J; Levin M; Douek ML; Beckett KR; Zanocco KA; Cheung DS; Gofnung YA; Smooke-Praw S; Yeh MW
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2261-2268. PubMed ID: 29590358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules.
    Yang SP; Nga ME; Bundele MM; Chiosea SI; Tan SH; Lum JHY; Parameswaran R; Lim MY; Li H; Cheah WK; Sek KS; Tan ATH; Loh TKS; Ngiam KY; Tan WB; Huang X; Ho TWT; Lim KH; Lim CM; Singaporewalla RM; Rao AD; Rao NCL; Chua DYK; Chin DC; Wald AI; LiVolsi VA; Nikiforov YE; Tai ES
    Cancer Cytopathol; 2024 May; 132(5):309-319. PubMed ID: 38319805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3.
    Kim NE; Raghunathan RS; Hughes EG; Longstaff XR; Tseng CH; Li S; Cheung DS; Gofnung YA; Famini P; Wu JX; Yeh MW; Livhits MJ
    J Clin Endocrinol Metab; 2023 Aug; 108(9):e698-e703. PubMed ID: 36995878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial.
    Livhits MJ; Zhu CY; Kuo EJ; Nguyen DT; Kim J; Tseng CH; Leung AM; Rao J; Levin M; Douek ML; Beckett KR; Cheung DS; Gofnung YA; Smooke-Praw S; Yeh MW
    JAMA Oncol; 2021 Jan; 7(1):70-77. PubMed ID: 33300952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.
    Nikiforova MN; Mercurio S; Wald AI; Barbi de Moura M; Callenberg K; Santana-Santos L; Gooding WE; Yip L; Ferris RL; Nikiforov YE
    Cancer; 2018 Apr; 124(8):1682-1690. PubMed ID: 29345728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
    Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
    Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utilities of
    Guan H; Toraldo G; Cerda S; Godley FA; Rao SR; McAneny D; Doherty G; Braverman L; Lee SL
    Thyroid; 2020 Apr; 30(4):536-547. PubMed ID: 31996097
    [No Abstract]   [Full Text] [Related]  

  • 28. Risk Stratification Study of Indeterminate Thyroid Nodules with a next-generation Sequencing Assay with Residual ThinPrep® Material.
    Zhao H; Jing W; Li W; Zhang Z; Cao J; Zhao L; Sun Y; Wang C; Wang Y; Guo H
    J Cancer; 2020; 11(24):7276-7282. PubMed ID: 33193891
    [No Abstract]   [Full Text] [Related]  

  • 29. Performance of a Multigene Genomic Classifier in Thyroid Nodules with Suspicious for Malignancy Cytology.
    Skaugen JM; Taneja C; Liu JB; Wald AI; Nikitski AV; Chiosea SI; Seethala RR; Ohori NP; Karslioglu-French E; Carty SE; Nikiforova MN; Yip L; Nikiforov YE
    Thyroid; 2022 Dec; 32(12):1500-1508. PubMed ID: 35864811
    [No Abstract]   [Full Text] [Related]  

  • 30. Thyroid cytology smear slides: An untapped resource for ThyroSeq testing.
    Nikiforova MN; Lepe M; Tolino LA; Miller ME; Ohori NP; Wald AI; Landau MS; Kaya C; Malapelle U; Bellevicine C; Troncone G; Nikiforov YE; Baloch Z
    Cancer Cytopathol; 2021 Jan; 129(1):33-42. PubMed ID: 32697051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of the ThyroSeq v3 Molecular Test in the Surgical Management of Thyroid Nodules in the Canadian Public Health Care Setting.
    Chen T; Gilfix BM; Rivera J; Sadeghi N; Richardson K; Hier MP; Forest VI; Fishman D; Caglar D; Pusztaszeri M; Mitmaker EJ; Payne RJ
    Thyroid; 2020 Sep; 30(9):1280-1287. PubMed ID: 32242511
    [No Abstract]   [Full Text] [Related]  

  • 32. Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management.
    Chiosea S; Hodak SP; Yip L; Abraham D; Baldwin C; Baloch Z; Gulec SA; Hannoush ZC; Haugen BR; Joseph L; Kargi AY; Khanafshar E; Livhits MJ; McIver B; Patel K; Patel SG; Randolph GW; Shaha AR; Sharma J; Stathatos N; van Zante A; Carty SE; Nikiforov YE; Nikiforova MN
    J Clin Endocrinol Metab; 2023 Oct; 108(11):2999-3008. PubMed ID: 37071871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The histologic outcomes of indeterminate thyroid nodules with rat sarcoma mutations: A case series.
    Jones M; Abendano DG; Turner M; Sullivan C; Reyes MCD
    Diagn Cytopathol; 2023 Dec; 51(12):E332-E337. PubMed ID: 37583345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A thyroid EIF1AX story: how clinical, cytologic, and molecular surveillance led to appropriate management.
    Geisler DL; Karslioglu French E; Yip L; Nikiforova MN; Nikiforov YE; Schoedel KE; Seethala RR; Ohori NP
    J Am Soc Cytopathol; 2023; 12(2):105-111. PubMed ID: 36504010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic performance of the second-generation molecular tests in the assessment of indeterminate thyroid nodules: A systematic review and meta-analysis.
    Lee E; Terhaar S; McDaniel L; Gorelik D; Gerhard E; Chen C; Ma Y; Joshi AS; Goodman JF; Thakkar PG
    Am J Otolaryngol; 2022; 43(3):103394. PubMed ID: 35241290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hürthle cell lesions on thyroid fine needle aspiration cytology: Molecular and histologic correlation.
    Schatz-Siemers N; Brandler TC; Oweity T; Sun W; Hernandez A; Levine P
    Diagn Cytopathol; 2019 Oct; 47(10):977-985. PubMed ID: 31293091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-operative features of non-invasive follicular thyroid neoplasms with papillary-like nuclear features: An analysis of their cytological, Gene Expression Classifier and sonographic findings.
    Song SJ; LiVolsi VA; Montone K; Baloch Z
    Cytopathology; 2017 Dec; 28(6):488-494. PubMed ID: 29165886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The negative outlook: Long-term follow up of ThyroSeq negative and low-risk nodules.
    Perry RA; Lee MF; Jug RC; Dash RC; Rocke DJ; Jiang XS
    Cancer Cytopathol; 2024 Jun; ():. PubMed ID: 39031857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular Testing of Nodules with a Suspicious or Malignant Cytologic Diagnosis in the Setting of Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP).
    Strickland KC; Eszlinger M; Paschke R; Angell TE; Alexander EK; Marqusee E; Nehs MA; Jo VY; Lowe A; Vivero M; Hollowell M; Qian X; Wieczorek T; French CA; Teot LA; Cibas ES; Lindeman NI; Krane JF; Barletta JA
    Endocr Pathol; 2018 Mar; 29(1):68-74. PubMed ID: 29396809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier.
    Hang JF; Westra WH; Cooper DS; Ali SZ
    Cancer Cytopathol; 2017 Sep; 125(9):683-691. PubMed ID: 28544601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.